CSIMarket
 


Prometheus Biosciences Inc   (RXDX)
Other Ticker:  
 

Prometheus Biosciences Inc 's Leverage Ratio

RXDX's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to repayements of liabilities of -6.18% Prometheus Biosciences Inc improved Leverage Ratio in third quarter 2023 to 0.09, below the company's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 67 other companies have achieved lower Leverage Ratio than Prometheus Biosciences Inc in the III Quarter 2023. While Leverage Ratio total ranking has deteriorated compared to the forth quarter 2022 from 54 to 215 .

Explain Leverage Ratio?
Who are RXDX Customers?
What are RXDX´s Total Liabilities?


RXDX Leverage Ratio (Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
Y / Y Equity Change 237.46 % 187.46 % -11.28 % -32.08 % -31.14 %
Y / Y Total Liabilities Change 29.75 % 143.66 % 218.4 % 63.4 % 170.06 %
Leverage Ratio MRQ 0.09 0.1 0.28 0.24 0.23
RXDX's Total Ranking # 215 # 54 # 711 # 726 # 527
Seq. Equity Change 3.2 % 190.7 % 21.22 % -7.2 % -12.09 %
Seq. Total Liabilities Change -6.18 % -1.93 % 44.42 % -2.35 % 76.18 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 68
Healthcare Sector # 112
Overall Market # 215


Leverage Ratio Statistics
High Average Low
89.72 3.64 0.06
(Sep 30 2013)  




Financial Statements
Prometheus Biosciences Inc 's Equity $ 698 Millions Visit RXDX's Balance sheet
Prometheus Biosciences Inc 's Total Liabilities $ 61 Millions Visit RXDX's Balance sheet
Source of RXDX's Sales Visit RXDX's Sales by Geography


Cumulative Prometheus Biosciences Inc 's Leverage Ratio

RXDX's Leverage Ratio for the trailling 12 Months

RXDX Leverage Ratio

(Mar 31 2023)
III. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
(Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
Y / Y Equity TTM Growth 237.46 % 187.46 % -11.28 % -32.08 % -31.14 %
Y / Y Total Liabilities TTM Growth 29.75 % 143.66 % 218.4 % 63.4 % 170.06 %
Leverage Ratio TTM 0.13 0.17 0.21 0.16 0.12
Total Ranking TTM # 167 # 117 # 466 # 433 # 2
Seq. Equity TTM Growth 3.2 % 190.7 % 21.22 % -7.2 % -12.09 %
Seq. Total Liabilities TTM Growth -6.18 % -1.93 % 44.42 % -2.35 % 76.18 %


On the trailing twelve months basis Due to repayements of liabilities of -6.18% Prometheus Biosciences Inc decreased Leverage Ratio in the 12 months ending in III Quarter 2023 to 0.13, below the company's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 60, during the past 12 months, other companies have achieved lower Leverage Ratio than Prometheus Biosciences Inc . While Leverage Ratio total ranking has deteriorated during the twelve months ending in the III Quarter 2023, compared to the prior period, from 117 to 167.

Explain Leverage Ratio?
Who are RXDX Customers?
What are RXDX´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 61
Healthcare Sector # 94
Within the Market # 167


trailing twelve months Leverage Ratio Statistics
High Average Low
0.63 0.3 0.1
(Sep 30 2017)   (Dec 31 2021)




Companies with similar Leverage Ratio in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Leverage RatioMar 31 2023 MRQ Total LiabilitiesMar 31 2023 MRQ Equity
Abcellera Biologics Inc   0.24 $ 289.419  Millions$ 1,208.500  Millions
Taro Pharmaceutical Industries Ltd  0.23 $ 404.654  Millions$ 1,730.859  Millions
Anebulo Pharmaceuticals Inc   0.23 $ 2.982  Millions$ 12.942  Millions
United Therapeutics Corporation  0.23 $ 1,176.500  Millions$ 5,123.200  Millions
Regeneron Pharmaceuticals Inc   0.23 $ 5,332.900  Millions$ 23,495.200  Millions
Arrowhead Pharmaceuticals Inc   0.23 $ 105.485  Millions$ 465.106  Millions
Lianbio  0.23 $ 61.930  Millions$ 274.427  Millions
Aldeyra Therapeutics Inc   0.22 $ 30.785  Millions$ 137.243  Millions
Prothena Corporation Public Limited Company  0.22 $ 134.177  Millions$ 607.409  Millions
Catalyst Pharmaceuticals Inc   0.22 $ 73.566  Millions$ 333.661  Millions
Pepgen Inc   0.22 $ 36.198  Millions$ 164.843  Millions
Bio path Holdings inc   0.22 $ 1.995  Millions$ 9.107  Millions
Sanofi  0.22 $ 18,148.480  Millions$ 83,275.360  Millions
Lumos Pharma Inc   0.21 $ 11.206  Millions$ 52.519  Millions
Processa Pharmaceuticals Inc   0.21 $ 2.161  Millions$ 10.142  Millions
Erasca Inc   0.21 $ 81.090  Millions$ 386.452  Millions
Lipella Pharmaceuticals Inc   0.21 $ 0.798  Millions$ 3.816  Millions
Rain Oncology Inc   0.21 $ 19.621  Millions$ 94.557  Millions
Spruce Biosciences Inc   0.21 $ 22.397  Millions$ 107.997  Millions
Annovis Bio inc   0.21 $ 4.153  Millions$ 20.136  Millions
Aileron Therapeutics Inc   0.20 $ 2.884  Millions$ 14.273  Millions
Pyxis Oncology Inc   0.20 $ 30.640  Millions$ 152.163  Millions
Geovax Labs Inc   0.20 $ 4.539  Millions$ 22.865  Millions
Mirati Therapeutics Inc   0.20 $ 171.131  Millions$ 862.630  Millions
Xilio Therapeutics inc   0.20 $ 16.819  Millions$ 84.792  Millions
Alterity Therapeutics Limited  0.20 $ 4.505  Millions$ 22.813  Millions
Protagenic Therapeutics Inc new  0.20 $ 1.252  Millions$ 6.414  Millions
Enanta Pharmaceuticals Inc  0.19 $ 52.147  Millions$ 269.375  Millions
Dyne Therapeutics Inc   0.19 $ 46.707  Millions$ 241.935  Millions
Corvus Pharmaceuticals Inc   0.19 $ 9.330  Millions$ 48.867  Millions

Date modified: 2023-05-11T17:18:02+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com